Aripiprazole
Product Images NDC 50090-5839

This is a list and a chart showing the effect of various drugs on Aripiprazole, a medication used to treat mental disorders. The drugs listed include inhibitors and inducers of certain enzymes that affect the metabolism of Aripiprazole, as well as other medications that may interact with it. The chart shows the fold change and confidence intervals for Aripiprazole when taken with each of these drugs, relative to when taken without any interacting drugs.*

This text provides a list of drugs and their effects on Aripiprazole, a medication used to treat psychiatric disorders. The drugs listed include inhibitors and inducers of CYP enzymes, gastric acid blockers, and other medications such as valproate and lorazepam. The Dehydro-Aripiprazole Fold Change and 90% CI chart shows the change in Aripiprazole concentration when taken with the interacting drugs relative to its reference concentration.*

This text appears to be a scientific document detailing research on how different populations metabolize a particular substance (possibly a medication) and how this affects its efficacy. The text includes comparisons between "poor" and "extensive" metabolizers in the context of a certain enzyme (CYP206), as well as comparisons between genders and age groups. It also discusses the effects of differing levels of hepatic and renal impairment on the substance, with the most severe being associated with lower levels of efficacy. Finally, the document looks at the "fold change" and "percent change" in the substance under different conditions. Overall, this appears to be a technical document aimed at scientists and medical professionals.*

This is a table of pharmacogenetic and pharmacokinetic data that compares the effect of different variables on the metabolism and absorption of a drug. The variables being compared are poor vs. extensive metabolizer status of CYP2D6, gender (male vs. female), age (16-64 vs. >65 years old), hepatic impairment (mild, moderate, severe vs. normal), and renal impairment (severe vs. normal). The measurements taken are AUC, max, and fold change with 90% confidence intervals for dehydro-aripiprazole. It appears to be a study evaluating the impact of various factors on drug metabolism and pharmacokinetics.*

This looks like a graph or a chart with two columns labelled "Ariplprazole" and "PLACEBO". The rows have numbers ranging from 0 to 1.0 with increments of 0.1, and there is a line graph showing the "Proportion with Relapse" for both Ariplprazole and PLACEBO at different intervals of time. The X-axis is labelled "Days from Randomization". The number of subjects at risk is also mentioned for both groups. It's likely a study comparing the effectiveness of Ariplprazole versus Placebo in preventing relapse.*

This text appears to be a graph or chart consisting of values and labels for a medication called Avripiprazole and a placebo. The chart includes proportional values with relapse, the number of subjects at risk, and days from randomization. However, without further context or a visual representation of the graph, it is not possible to provide a more detailed description.*

This text appears to be a table displaying the proportion of subjects with relapse and number of subjects at risk for a drug called Aripiprazole and a placebo. The table also shows the number of days from randomization. Therefore, this may be a study on the efficacy of Aripiprazole compared to a placebo for preventing relapse in a certain condition.*

This appears to be the label of a medication called "ARYptpRAZOLE 5 MG" with a product number of "6703-0". The label also indicates that there are 30 tablets per bottle. However, the other parts of the text are not clear and are difficult to understand.*